prikaz prve stranice dokumenta Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study
Pristup korisnicima matične ustanove
Znanstveni rad - Izvorni znanstveni rad
Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study
Diabetes Research and Clinical Practice, 177 (2021); 108884. https://doi.org/10.1016/j.diabres.2021.108884
Mikolasevic, I.; Rahelic, D.; Turk-Wensween, T.; Ruzic, A.; Domislovic, V.; Hauser, G.; Matic, T.; Radic-Kristo, D.; Krznaric, Z.; Radic, M.; Filipec Kanizaj, T.; Martinovic, M.; Jerkic, H.; Medjimurec, M.; Targher, G. Više autora...

Citirajte ovaj rad

Mikolasevic, I., Rahelic, D., Turk Wensween, T., Ruzic, A., Domislovic, V., Hauser, G. ... Targher, G. (2021). Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study. Diabetes Research and Clinical Practice, 177., 108884. doi: 10.1016/j.diabres.2021.108884

Mikolasevic, I., et al. "Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study." Diabetes Research and Clinical Practice, vol. 177, 2021, str. 108884. https://doi.org/10.1016/j.diabres.2021.108884

Mikolasevic, I., D. Rahelic, T. Turk Wensween, A. Ruzic, V. Domislovic, G. Hauser, T. Matic, et al. "Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study." Diabetes Research and Clinical Practice 177 (2021): 108884. https://doi.org/10.1016/j.diabres.2021.108884

Mikolasevic, I., et al. (2021) 'Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study', Diabetes Research and Clinical Practice, 177, str. 108884. doi: 10.1016/j.diabres.2021.108884

Mikolasevic I, Rahelic D, Turk Wensween T, Ruzic A, Domislovic V, Hauser G, i sur.. Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study. Diabetes Research and Clinical Practice [Internet]. 07.2021. [pristupljeno 14.12.2024.];177:108884. doi: 10.1016/j.diabres.2021.108884

I. Mikolasevic, et al., "Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study", Diabetes Research and Clinical Practice, vol. 177, str. 108884, Srpanj 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:264:519541. [Citirano: 14.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:264:519541
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study
AutorI. Mikolasevic
AutorD. Rahelic
AutorT. Turk-Wensween
AutorA. Ruzic
AutorV. Domislovic
AutorG. Hauser
AutorT. Matic
AutorD. Radic-Kristo
AutorZ. Krznaric
AutorM. Radic
AutorT. Filipec Kanizaj
MBZ: 272175
AutorM. Martinovic
AutorH. Jerkic
AutorM. Medjimurec
AutorG. Targher
Autorova ustanova(Klinička bolnica Merkur)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
AimsThe aim of this study was to investigate whether controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), as assessed by vibration-controlled transient elastography (VCTE), are associated with chronic vascular complications of diabetes mellitus type 2 (T2DM). Methods We studied 442 outpatients with established T2DM, and who underwent VCTE and extensive assessment of chronic vascular complications of diabetes. ResultsA quarter of analyzed patients had a previous history of myocardial infarction and/or ischemic stroke, and about half of them had at least one microvascular complication (chronic kidney disease (CKD), retinopathy or polyneuropathy). The prevalence of liver steatosis (i.e., CAP ≥ 238 dB/m) and significant liver fibrosis (i.e., LSM ≥ 7.0/6.2 kPa) was 84.2% and 46.6%, respectively. Significant liver fibrosis was associated with an increased likelihood of having myocardial infarction (adjusted-odds ratio 6.61, 95%CI 1.66–37.4), peripheral polyneuropathy (adjusted-OR 4.55, 95%CI 1.25–16.6), CKD (adjusted-OR 4.54, 95%CI 1.24–16.6) or retinopathy (adjusted-OR 1.81, 95%CI 1.62–1.97), independently of cardiometabolic risk factors, diabetes-related variables, and other potential confounders. Liver steatosis was not independently associated with any macro-/microvascular diabetic complications. ConclusionsSignificant liver fibrosis is strongly associated with the presence of macro-/microvascular complications in patients with T2DM. These results offer a new perspective on the follow-up of people with T2DM.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaDiabetes Research and Clinical Practice
Brojčani podacivol. 177, str. 108884
p-ISSN0168-8227
DOIhttps://doi.org/10.1016/j.diabres.2021.108884
URN:NBNurn:nbn:hr:264:519541
Datum objave publikacije2021-07
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S0168822721002448
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-12-06 09:10:35